Acute ischemic stroke (AIS) is a leading cause of death and disability across the US and around the world.
1 Treatments for AIS are currently limited to reperfusion therapies: intravenous thrombolysis and endovascular thrombectomy. Many patients are not candidates for these therapies, and among those who receive them, the rate of excellent outcome remains low; only 20% to 30% are free from disability at 3 months poststroke.
2-4 Therefore, there is a critical need to develop additional therapies for patients with AIS. In animal models of acute cerebral ischemia, cathodal transcranial direct current stimulation (C-tDCS) salvages ischemic tissue at risk of infarction, both through direct neuroprotection by inhibiting peri-infarct excitotoxic effects, inflammatory and apoptotic pathways,
5 and through collateral perfusion enhancement by inducing vasodilation.
6 C-tDCS has many advantages over existing therapies. Delivery of pharmacological agents to threatened tissues is constrained by the same blood flow diminution that is producing ischemia. In contrast, C-tDCS is a regionally directed therapy that instantly reaches maximum local concentration.
7 In addition, via high-definition (HD) electrode montages, electrical field shape and coverage location can be tailored to the ischemic tissue at risk of infarction.